Richard J Nowak
Overview
Explore the profile of Richard J Nowak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
2447
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ting A, Park M, Sangha O, Kumar M, Ricci J, Lee E, et al.
Neurol Ther
. 2025 Feb;
14(2):575-591.
PMID: 39961947
Introduction: Limited data are available on the relationship between myasthenia gravis (MG) severity and MG exacerbations and healthcare resource utilization (HCRU) following exacerbations. The objective of this study was to...
2.
Antozzi C, Vu T, Ramchandren S, Nowak R, Farmakidis C, Bril V, et al.
Lancet Neurol
. 2025 Jan;
24(2):105-116.
PMID: 39862879
Background: Given burdensome side-effects and long latency for efficacy with conventional agents, there is a continued need for generalised myasthenia gravis treatments that are safe and provide consistently sustained, long-term...
3.
G Brew S, Frey M, P McCarthy D, Elhofy A, Nowak R
BMJ Neurol Open
. 2024 Dec;
6(2):e000836.
PMID: 39720510
Introduction: Myasthenia gravis (MG) is a T cell-dependent B cell-mediated autoimmune disease with pathogenic antibodies directed against components of the acetylcholine receptor (AChR). Current therapies do not address the root...
4.
Garbey M, Lesport Q, Girma H, Oztosun G, Abu-Rub M, Guidon A, et al.
Front Neurol
. 2024 Dec;
15:1474884.
PMID: 39697445
Background: Advances in video image analysis and artificial intelligence provide opportunities to transform how patients are evaluated. In this study, we assessed the ability to quantify Zoom video recordings of...
5.
Zivkovic S, Nowak R, DiCapua D
Neuromuscul Disord
. 2024 Dec;
47:105254.
PMID: 39693713
Axonal Charcot-Marie-Tooth disease (CMT2) and distal hereditary motor neuropathy (dHMN) are associated with a heterogeneous group of genes encoding proteins that are involved in axonal transport, control of RNA metabolism,...
6.
Nowak R, Habib A, Klink A, Muppidi S, Parthan A, Sader S, et al.
Drugs Real World Outcomes
. 2024 Oct;
11(4):593-601.
PMID: 39470958
Background And Objective: The terminal complement inhibitor eculizumab is approved in the USA for the treatment of patients with acetylcholine receptor antibody-positive generalized myasthenia gravis (MG). The ELEVATE study aimed...
7.
Baxter L, Hopkins S, OConnor K, Pham M, Nowak R, Monson N, et al.
J Neuroimmunol
. 2024 Sep;
396:578454.
PMID: 39277987
Autoimmune autonomic ganglionopathy (AAG) is a rare disease wherein autoantibodies target the ganglionic acetylcholine receptor (gAChR). Current diagnosis in the United States depends upon clinical symptoms and positive autoantibody detection...
8.
Habib A, Klink A, Muppidi S, Parthan A, Sader S, Balanean A, et al.
J Neurol
. 2024 Jul;
271(9):6114-6126.
PMID: 39052039
Background/objectives: The phase 3 REGAIN study and its open-label extension demonstrated the efficacy of the complement C5 inhibitor eculizumab in patients with treatment-refractory, acetylcholine receptor antibody-positive generalized myasthenia gravis (gMG)....
9.
Bodansky A, Yu D, Rallistan A, Kalaycioglu M, Boonyaratanakornkit J, Green D, et al.
J Clin Invest
. 2024 May;
134(13).
PMID: 38753445
Given the global surge in autoimmune diseases, it is critical to evaluate emerging therapeutic interventions. Despite numerous new targeted immunomodulatory therapies, comprehensive approaches to apply and evaluate the effects of...
10.
Howard Jr J, Bresch S, Farmakidis C, Freimer M, Genge A, Hewamadduma C, et al.
Ther Adv Neurol Disord
. 2024 Apr;
17:17562864241243186.
PMID: 38638673
Background: Generalized myasthenia gravis (gMG) is a chronic, unpredictable disease associated with high treatment and disease burdens, with a need for more effective and well-tolerated treatments. Objectives: To evaluate the...